- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03054805
The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators performed a monocentric, prospective, randomized controlled trial including 120 pediatric patients (aged 6 months - 10 years old) with functional constipation and 30 healthy age-matched healthy children as control. The investigators shall evaluate the children according to the Rome III Diagnostic Criteria for functional constipation.
The 120 enrolled patients are randomized in to two groups: Group A receiving magnesium oxide and probiotics (MIYAIRI-BM), Group B receiving only magnesium oxide. Each patient is assigned the evaluation constipation symptoms and detection of microflora (beneficial and harmful bacteria) in fecal samples at the enrollment, 4 weeks, and 12 weeks. Patients who take less than 80% of the appropriate dose of medications are withdrawn from the study. All patients included in the study will be given informed oral consent before entering the study.
The data of the fecal microflora evaluated in 60 healthy children are used as control.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Rome III Diagnostic Criteria for functional constipation for children aged 6 months - 4 years old is as the following:
- Two or fewer defecations per week.
- At least one episode per week of incontinence after acquiring toileting skills.
- History of excessive stool retention.
- History of painful or hard bowel movements.
- Presence of a large fecal mass in the rectum.
- History of large-diameter stools that may obstruct the toilet. Children aged 6 months - 4 years old is evaluated as functional constipation if two of the situations mentioned above lasted for one month.
Rome III Diagnostic Criteria for functional constipation for children aged 4 years old and above is as the following:
- Two or fewer defecations in the toilet per week.
- At least one episode of fecal incontinence per week.
- History of retentive posturing or excessive volitional stool retention.
- History of painful or hard bowel movements.
- Presence of a large fecal mass in the rectum.
- History of large diameter stools that may obstruct the toilet. Children aged 4 years old and above is evaluated as functional constipation if two of the situations mentioned above happens at least once per week
Exclusion Criteria:
- gastroesophageal reflux disease
- inflammatory bowel disease
- cardiopulmonary diseases
- liver disease
- renal disease
- genetic diseases
- endocrinal diseases
- received abdominal surgeries
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Magnesium oxide and MIYAIRI-BM
Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks. MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks. |
Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
Other Names:
MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
Other Names:
|
|
Active Comparator: Magnesium oxide
MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
|
Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
Other Names:
|
|
No Intervention: Healthy Children
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children.
Time Frame: Change from baseline Clostridium butyricum Miyairi expression at 3 months.
|
The expression of Clostridium butyricum Miyairi (CBM) in constipated children feces means a better outcome measure.
|
Change from baseline Clostridium butyricum Miyairi expression at 3 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 103-0519A3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Constipation
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Liaquat University of Medical & Health SciencesUniversità degli Studi dell'InsubriaNot yet recruiting
-
Universidad de AntioquiaNot yet recruitingConstipation - Functional
-
Eskisehir Osmangazi UniversitySehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research HospitalCompletedConstipation - FunctionalTurkey (Türkiye)
-
Ahi Evran University Education and Research HospitalActive, not recruitingConstipation - FunctionalTurkey (Türkiye)
-
Wecare Probiotics Co., Ltd.Not yet recruiting
-
Federal University of Minas GeraisMax NutriRecruiting
-
Peking Union Medical College HospitalInstitute of Process Engineering, Chinese Academy of SciencesNot yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota TransplantationChina
-
Peking Union Medical College HospitalRecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)China
-
Zeynep Idil SevimliNot yet recruitingFunctional Constipation (FC)Turkey (Türkiye)
Clinical Trials on Magnesium Oxide
-
Scarborough General HospitalLakeridge Health Corporation; Scarborough Health NetworkRecruiting
-
Sultan Qaboos UniversityNova BiomedicalCompletedType 2 Diabetes | Magnesium DisorderOman
-
University of PadovaCompleted
-
University of WorcesterCoventry University; Beijing Sport UninversityCompletedMagnesium DeficiencyUnited Kingdom
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast Cancer | Hot Flashes | Cancer SurvivorUnited States
-
Think Healthy Group, Inc.Indiana UniversityCompleted
-
Universidad Nacional Autonoma de MexicoHospital Infantil de Mexico Federico Gomez; Centro de Investigación y Estudios...UnknownFebrile NeutropeniaMexico
-
Coordinación de Investigación en Salud, MexicoCompletedObesity | Vascular RiskMexico
-
Bionos Biotech S.L.Completed